These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 8622074)

  • 1. Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity.
    Ribas A; Albanell J; Bellmunt J; Solé-Calvo LA; Bermejo B; Gallardo E; Vidal R; Vera R; Eres N; Carulla J; Baselga J
    J Clin Oncol; 1996 May; 14(5):1573-80. PubMed ID: 8622074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
    Jones SE; Schottstaedt MW; Duncan LA; Kirby RL; Good RH; Mennel RG; George TK; Snyder DA; Watkins DL; Denham CA; Hoyes FA; Rubin AS
    J Clin Oncol; 1996 Nov; 14(11):2976-83. PubMed ID: 8918495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose intensity of standard adjuvant CMF with granulocyte colony-stimulating factor for premenopausal patients with node-positive breast cancer.
    de Graaf H; Willemse PH; Bong SB; Piersma H; Tjabbes T; van Veelen H; Coenen JL; de Vries EG
    Oncology; 1996; 53(4):289-94. PubMed ID: 8692532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent dose delays and growth factor requirements with the sequential doxorubicin-CMF schedule.
    Ribas A; Albanell J; Bellmunt J; Bermejo B; Gallardo E; Vera R; Bodi R; Solé-Calvo LA
    Acta Oncol; 1997; 36(7):701-4. PubMed ID: 9490086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Feasibility of a cyclophosphamide methotrexate and 5-fluorouracil regime intravenously administered with and without granulocyte-colony stimulating factor in surgically treated breast carcinoma].
    Garrone O; Del Mastro L; Mariani GL; Ardizzoni A; Venturini M; Rosso R
    Minerva Med; 1993 Sep; 84(9):467-72. PubMed ID: 7504219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
    Nabholtz JM; Cantin J; Chang J; Guevin R; Patel R; Tkaczuk K; Vodvarka P; Lindsay MA; Reese D; Riva A; Mackey J
    Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen.
    Mattioli R; Gridelli C; Castellanos J; Duque A; Falcone A; Mansutti M; Bacon P; Lawrinson S; Skacel T; Casas A
    Clin Transl Oncol; 2009 Dec; 11(12):842-8. PubMed ID: 20045791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer.
    Cousin S; Le Rhun E; Mailliez A; Fournier C; Bonneterre J
    Bull Cancer; 2012; 99(7-8):75-80. PubMed ID: 22713627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with metastatic or high-risk primary breast cancer. National Surgical Adjuvant Breast and Bowel Project.
    Mamounas EP; Anderson S; Wickerham DL; Clark R; Stoller R; Hamm JT; Stewart JA; Bear HD; Glass AG; Bornstein R
    Am J Clin Oncol; 1994 Oct; 17(5):374-81; discussion 382. PubMed ID: 7522393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute hematologic feasibility of G-CSF supported dose-escalated FEC therapy as adjuvant treatment after breast cancer surgery.
    Ottosson S; Magnusson K; Hultborn R
    Anticancer Res; 1999; 19(5C):4429-34. PubMed ID: 10650787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
    Crawford J; Ozer H; Stoller R; Johnson D; Lyman G; Tabbara I; Kris M; Grous J; Picozzi V; Rausch G
    N Engl J Med; 1991 Jul; 325(3):164-70. PubMed ID: 1711156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.
    O'Shaughnessy JA; Denicoff AM; Venzon DJ; Danforth D; Pierce LJ; Frame JN; Bastian A; Ghosh B; Goldspiel B; Miller L
    Ann Oncol; 1994 Oct; 5(8):709-16. PubMed ID: 7826903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermittent granulocyte colony-stimulating factor maintains dose intensity after ABVD therapy complicated by neutropenia.
    Ho P; Sherman P; Grigg A
    Eur J Haematol; 2012 May; 88(5):416-21. PubMed ID: 22296221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer--further observations from the IMPACT solid study.
    Mäenpää J; Varthalitis I; Erdkamp F; Trojan A; Krzemieniecki K; Lindman H; Bendall K; Vogl FD; Verma S
    Breast; 2016 Feb; 25():27-33. PubMed ID: 26801413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
    Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of granulocyte colony-stimulating factor (filgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin's disease.
    Silvestri F; Fanin R; Velisig M; Barillari G; Virgolini L; Zaja F; Russo D; Baccarani M
    Tumori; 1994 Dec; 80(6):453-8. PubMed ID: 7534963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia.
    Michel G; Landman-Parker J; Auclerc MF; Mathey C; Leblanc T; Legall E; Bordigoni P; Lamagnere JP; Demeocq F; Perel Y; Auvrignon A; Berthou C; Bauduer F; Pautard B; Schneider P; Schaison G; Leverger G; Baruchel A
    J Clin Oncol; 2000 Apr; 18(7):1517-24. PubMed ID: 10735900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant moderately high-dose chemotherapy with rh-G-CSF in locally advanced breast carcinoma.
    Fornasiero A; Ghiotto C; Daniele O; Favaretto AG; D'Amanzo P; Ziade A
    Tumori; 2001; 87(4):223-8. PubMed ID: 11693799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
    Yu JL; Chan K; Kurin M; Pasetka M; Kiss A; Sridhar SS; Warner E
    Breast J; 2015; 21(6):658-64. PubMed ID: 26387577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
    Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.